Business Context and Reporting Period
This Form 10-Q covers the quarterly period ended September 30, 2006, for HAPC, Inc. (formerly Healthcare Acquisition Partners Corp.), a Delaware corporation operating as a blank check company (SPAC). The Company's objective is to acquire one or more operating businesses primarily in the healthcare sector. As of the filing date, the Company had not yet consummated a business combination but had entered into a definitive agreement to acquire InfuSystem, Inc.
Key Financial Metrics
| Metric | Three Months Ended Sep 30, 2006 | Nine Months Ended Sep 30, 2006 | Balance Sheet (Sep 30, 2006) |
|---|---|---|---|
| Revenues | $0 | $0 | N/A |
| Net Loss | $(13,582,230) | $(17,478,072) | N/A |
| Interest Income | $1,174,645 | $2,031,677 | N/A |
| Cash and Cash Equivalents | N/A | N/A | $609,232 |
| Investments Held in Trust | N/A | N/A | $97,625,231 |
| Total Assets | N/A | N/A | $98,969,557 |
| Total Liabilities | N/A | N/A | $5,483,100 |
| Stockholders' Equity | N/A | N/A | $73,971,173 |
Note: The Company reported no operating revenues. Expenses were primarily non-cash stock-based compensation and general administrative costs.
Material Changes vs. Prior Period
- Capitalization: The Company consummated its Initial Public Offering (IPO) on April 18, 2006, raising gross proceeds of approximately $100 million. This resulted in a significant increase in total assets from $178,678 at December 31, 2005, to $98.97 million at September 30, 2006.
- Trust Account: Approximately $96.2 million of IPO proceeds were deposited into a Trust Account, invested in U.S. government securities. As of September 30, 2006, the Trust Account balance was $97.6 million, including interest income.
- Net Loss: The Company incurred a net loss of $17.5 million for the nine months ended September 30, 2006, compared to a negligible loss of $56 for the period from inception to September 30, 2005. The 2006 loss was driven by non-cash expenses related to stock-based compensation ($13.0 million for director grants and $5.5 million for amortization) and offering costs.
- Debt: Notes payable outstanding at December 31, 2005 ($85,000) were paid in full in May 2006. As of September 30, 2006, there were no outstanding notes payable.
Outlook, Management Commentary, and Risks
Definitive Agreement
On September 29, 2006, the Company entered into a Stock Purchase Agreement to acquire InfuSystem, Inc. for a purchase price of $140 million. The consideration includes:
- A secured promissory note to I-Flow (parent of InfuSystem) ranging from $55 million to $75 million, depending on shareholder redemptions.
- Cash payment of approximately $65 million plus adjustments.
- A $100,000 delivery fee paid to I-Flow on October 4, 2006.
Stockholder Approval and Redemption Rights
The acquisition requires approval by a majority of public stockholders. If 20% or more of public shares are redeemed, the transaction will not be consummated. If approved and less than 20% are redeemed, redeeming shareholders receive a pro-rata share of the Trust Account.
Risks and Contingencies
- Liquidation Risk: If the acquisition is not approved or consummated by April 18, 2008 (or April 30, 2007 under the agreement terms), the Company must liquidate. In a liquidation, shareholders may receive less than the $6.00 IPO price due to expenses, and warrants will expire worthless.
- Leverage: Post-acquisition, the Company will be highly leveraged with debt between $55 million and $75 million, which could limit operational flexibility and increase vulnerability to economic downturns.
- Break-Up Fee: If the agreement is terminated due to failure to obtain stockholder approval or inability to consummate the deal, the Company must pay a break-up fee of $1 million to $3 million to I-Flow, guaranteed by two directors.
- Internal Controls: Management identified material weaknesses in internal controls over financial reporting, necessitating a restatement of prior financial statements (April 18, 2006, and June 30, 2006) to properly classify conversion rights as mezzanine equity.
Investor Verification Checklist
- Verify the status of the stockholder vote required to approve the InfuSystem acquisition.
- Confirm the final redemption rate of public shares to determine the exact principal amount of the promissory note ($55M–$75M).
- Review the terms of the $3 million break-up fee guarantee provided by directors Sean McDevitt and Philip Harris.
- Assess the impact of the identified material weaknesses in internal controls on future financial reporting reliability.
- Monitor the Company's ability to secure alternative financing if the InfuSystem deal fails, given the limited time remaining before the mandatory liquidation date.